Impact of probiotic Veillonella atypica FB0054 supplementation on anaerobic capacity and lactate
Kristen Gross,
Marina Santiago,
Joesi M. Krieger,
Anthony M. Hagele,
Kinga Zielinska,
Jonathan Scheiman,
Ralf Jäger,
Alex Kostic,
Chad M. Kerksick
Affiliations
Kristen Gross
Exercise and Performance Nutrition Laboratory, Kinesiology Department, College of Science, Technology, and Health, Lindenwood University, St. Charles, MO, USA
Marina Santiago
FitBiomics, Inc, New York City, NY, USA
Joesi M. Krieger
Exercise and Performance Nutrition Laboratory, Kinesiology Department, College of Science, Technology, and Health, Lindenwood University, St. Charles, MO, USA
Anthony M. Hagele
Exercise and Performance Nutrition Laboratory, Kinesiology Department, College of Science, Technology, and Health, Lindenwood University, St. Charles, MO, USA
Kinga Zielinska
FitBiomics, Inc, New York City, NY, USA; Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK
Jonathan Scheiman
FitBiomics, Inc, New York City, NY, USA
Ralf Jäger
Increnovo, LLC, Whitefish Bay, WI, USA
Alex Kostic
FitBiomics, Inc, New York City, NY, USA; Department of Microbiology, Harvard Medical School, Boston, MA, USA; Section on Pathophysiology and Molecular Pharmacology, Joslin Diabetes Center, Boston, MA, USA
Chad M. Kerksick
Exercise and Performance Nutrition Laboratory, Kinesiology Department, College of Science, Technology, and Health, Lindenwood University, St. Charles, MO, USA; Corresponding author
Summary: Seven healthy, physically active men (n = 3) and women (n = 4) (30.7 ± 7.5 years, 172.7 ± 8.7 cm, 70.4 ± 11.6 kg, 23.6 ± 4.1 kg/m2, 49.2 ± 8.4 mL/kg/min) supplemented for 14 days with a placebo (PLA) or 1 × 1010 CFU doses of the probiotic Veillonella atypica FB0054 (FitBiomics, New York, NY). Participants had safety panels, hemodynamics, lactate, and anaerobic capacity assessed. Stool samples were collected to evaluate for metagenomic and metabolomic changes. Exhaustion times were not different between groups, whereas anaerobic capacity tended to shorten with PLA (61.14 ± 72.04 s; 95% CI: −5.49, 127.77 s, p = 0.066) with no change with VA (13.29 ± 100.13 s, 95% CI: −79.32, 105.89 s, p = 0.738). No changes in lactate, hemodynamics, or bacterial community changes were observed, whereas 14 metabolites exhibited differential expression patterns with VA supplementation. In conclusion, VA maintained exercise performance that tended to decline in PLA. Supplementation was well tolerated with no changes in safety markers or reported adverse events.
